原发性醛固酮增多症患者手术与靶向药物治疗的获益时间:一项Meta分析
该Meta分析纳入16项研究、15541例原发性醛固酮增多症患者,比较肾上腺切除术与药物治疗的临床结局。手术与较低的死亡风险(HR 0.34,95%CI 0.22-0.54)和主要不良心血管事件(HR 0.55,95%CI 0.36-0.84)相关。绝对获益方面,每200例患者接受手术而非药物治疗,可在12.3个月(95%CI 3.1-48.7)后预防1例死亡。
要点
- 手术与药物治疗相比,全因死亡风险显著降低(HR 0.34,95%CI 0.22-0.54)。
- 手术与主要不良心血管事件风险显著降低相关(HR 0.55,95%CI 0.36-0.84)。
- 手术与心衰住院和慢性肾脏病进展风险降低相关,心肌梗死和卒中风险降低未达统计学显著。
核心结论
- 对于原发性醛固酮增多症患者,手术与药物治疗相比,全因死亡率和主要不良心血管事件风险较低。
- 对大多数患者而言,长期手术获益超过短期围手术期风险。
研究设计与样本
- 检索Medline和EMBASE数据库,纳入报告肾上腺切除术与药物治疗后死亡、主要不良心血管事件、慢性肾脏病进展或糖尿病发生率的原始研究。
- 共纳入16项研究、15541例原发性醛固酮增多症患者;由两名评价者独立提取数据并评估研究质量。
- 采用随机效应模型进行标准Meta分析以估计相对差异;通过拟合Weibull生存曲线进行获益时间Meta分析,估计绝对风险差异并采用随机效应模型合并。
主要发现
- 手术与药物治疗相比,全因死亡风险较低(HR 0.34,95%CI 0.22-0.54)。
- 手术与药物治疗相比,主要不良心血管事件风险较低(HR 0.55,95%CI 0.36-0.84)。
- 手术与心衰住院风险较低(HR 0.48,95%CI 0.34-0.70)和慢性肾脏病进展风险较低(HR 0.62,95%CI 0.39-0.98)相关。
- 手术与心肌梗死和卒中风险降低相关,但未达统计学显著。
- 绝对获益:每200例患者接受手术而非药物治疗,可在12.3个月(95%CI 3.1-48.7)后预防1例死亡。
关键数值与推荐
- 手术 vs 药物治疗:全因死亡 HR 0.34(95%CI 0.22-0.54)。
- 手术 vs 药物治疗:主要不良心血管事件 HR 0.55(95%CI 0.36-0.84)。
- 手术 vs 药物治疗:心衰住院 HR 0.48(95%CI 0.34-0.70)。
- 手术 vs 药物治疗:慢性肾脏病进展 HR 0.62(95%CI 0.39-0.98)。
- 预防1例死亡的需治疗人数为200例,获益时间为12.3个月(95%CI 3.1-48.7)。
临床怎么用
- 原文未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Primary aldosteronism (PA) is one of the most common causes of secondary hypertension, but the comparative outcomes of targeted treatment remain unclear. OBJECTIVE: To compare the clinical outcomes in patients treated for primary aldosteronism over time. METHODS: Medline and EMBASE were searched. Original studies reporting the incidence of mortality, major adverse cardiovascular outcomes (MACE), progression to chronic kidney disease, or diabetes following adrenalectomy vs medical therapy were selected. Two reviewers independently abstracted data and assessed study quality. Standard meta-analyses were conducted using random-effects models to estimate relative differences. Time to benefit meta-analyses were conducted by fitting Weibull survival curves to estimate absolute risk differences and pooled using random-effects models. RESULTS: 15 541 patients (16 studies) with PA were included. Surgery was consistently associated with an overall lower risk of death (hazard ratio [HR] 0.34, 95% CI 0.22-0.54) and MACE (HR 0.55, 95% CI 0.36-0.84) compared with medical therapy. Surgery was associated with a significantly lower risk of hospitalization for heart failure (HR 0.48 95% CI 0.34-0.70) and progression to chronic kidney disease (HR 0.62 95% CI 0.39-0.98), and nonsignificant reductions in myocardial infarction and stroke. In absolute terms, 200 patients would need to be treated with surgery instead of medical therapy to prevent 1 death after 12.3 (95% CI 3.1-48.7) months. CONCLUSION: Surgery is associated with lower all-cause mortality and MACE than medical therapy for PA. For most patients, the long-term surgical benefits outweigh the short-term perioperative risks.
引用
- Samnani S, Cenzer I, Kline GA, et al. Time to Benefit of Surgery vs Targeted Medical Therapy for Patients With Primary Aldosteronism: A Meta-analysis. J Clin Endocrinol Metab. 2024. PMID: 37946600. doi:10.1210/clinem/dgad654
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。